Stock listing
BX Swiss:RXRX Recursion Pharmaceuticals, Inc. Aktie
Swiss listing (BX Swiss) of Recursion Pharmaceuticals, Inc. · home listing NASDAQ:RXRX
Follow Recursion Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RXRX
$2.45 USD -0.38 (-13.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RXRX
- Day range
- $2.44 – $2.76 USDNov 20, 2026
- Volume
- 29.80M sharesNov 20, 2026
- Market cap
- $1.53B USDAt the close on Nov 20, 2026 · price × 622.8M shares outstanding
- 52-week range
- $2.44 – $5.24 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $89.94M USDMedian day 20.39M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RXRX · Home | $2.45 USD | -0.375 (-13.3%) | 29,797,529 | $2.63 | $2.76 | $2.44 | $2.825 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RXRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.45 | -0.375 | -13.3% | $2.63 | $2.76 | $2.44 | 29,797,529 | |
| $2.825 | +0.105 | +3.9% | $2.785 | $3.02 | $2.77 | 41,127,675 | |
| $2.72 | -0.185 | -6.4% | $2.945 | $2.945 | $2.50 | 40,745,536 | |
| $2.905 | -0.28 | -8.8% | $3.095 | $3.13 | $2.865 | 19,603,924 | |
| $3.185 | -0.145 | -4.4% | $3.33 | $3.34 | $3.16 | 16,526,938 | |
| $3.33 | -0.26 | -7.2% | $3.422 | $3.46 | $3.265 | 20,388,676 | |
| $3.59 | +0.04 | +1.1% | $3.685 | $3.72 | $3.53 | 16,483,995 | |
| $3.55 | -0.255 | -6.7% | $3.69 | $3.77 | $3.47 | 19,080,002 | |
| $3.805 | +0.285 | +8.1% | $3.52 | $3.87 | $3.47 | 20,321,698 | |
| $3.52 | +0.02 | +0.6% | $3.585 | $3.645 | $3.48 | 15,484,291 | |
| $3.50 | -0.38 | -9.8% | $3.79 | $3.795 | $3.42 | 25,236,618 | |
| $3.88 | +0.20 | +5.4% | $3.83 | $4.01 | $3.72 | 20,545,054 | |
| $3.68 | -0.15 | -3.9% | $3.855 | $4.08 | $3.65 | 20,658,666 | |
| $3.83 | -0.20 | -5.0% | $4.125 | $4.17 | $3.78 | 22,444,255 | |
| $4.03 | -0.21 | -5.0% | $4.05 | $4.16 | $3.785 | 24,357,781 | |
| $4.24 | -0.11 | -2.5% | $4.24 | $4.515 | $4.15 | 20,566,825 | |
| $4.35 | +0.30 | +7.4% | $4.00 | $4.43 | $3.995 | 28,353,942 | |
| $4.05 | +0.25 | +6.6% | $3.81 | $4.145 | $3.73 | 22,100,545 | |
| $3.80 | +0.10 | +2.7% | $3.72 | $3.86 | $3.64 | 16,055,282 | |
| $3.70 | +0.12 | +3.4% | $3.52 | $3.70 | $3.45 | 19,038,600 | |
| $3.58 | -0.06 | -1.6% | $3.54 | $3.68 | $3.485 | 17,735,700 | |
| $3.64 | -0.02 | -0.5% | $3.66 | $3.76 | $3.56 | 19,356,500 | |
| $3.66 | +0.05 | +1.4% | $3.555 | $3.67 | $3.47 | 20,925,100 | |
| $3.61 | +0.145 | +4.2% | $3.53 | $3.69 | $3.48 | 30,009,600 | |
| $3.465 | -0.695 | -16.7% | $4.11 | $4.185 | $3.44 | 40,724,300 | |
| $4.16 | +0.42 | +11.2% | $3.65 | $4.41 | $3.53 | 62,870,100 | |
| $3.74 | -0.095 | -2.5% | $3.72 | $3.91 | $3.66 | 18,783,700 | |
| $3.835 | -0.175 | -4.4% | $4.01 | $4.05 | $3.82 | 19,764,300 | |
| $4.01 | -0.35 | -8.0% | $4.31 | $4.365 | $3.91 | 23,785,300 | |
| $4.36 | +0.41 | +10.4% | $4.015 | $4.43 | $3.89 | 35,501,300 | |
| $3.95 | -0.32 | -7.5% | $4.19 | $4.20 | $3.79 | 30,898,400 | |
| $4.27 | -0.36 | -7.8% | $4.505 | $4.60 | $4.23 | 40,730,500 | |
| $4.63 | -0.15 | -3.1% | $4.81 | $5.19 | $4.395 | 71,106,000 | |
| $4.78 | +0.66 | +16.0% | $4.16 | $4.935 | $4.06 | 67,278,700 | |
| $4.12 | +0.05 | +1.2% | $4.18 | $4.27 | $4.01 | 18,840,000 | |
| $4.07 | -0.06 | -1.5% | $4.07 | $4.17 | $3.96 | 17,484,100 | |
| $4.13 | +0.10 | +2.5% | $4.09 | $4.29 | $3.98 | 32,785,900 | |
| $4.03 | +0.33 | +8.9% | $3.73 | $4.04 | $3.723 | 21,564,000 | |
| $3.70 | -0.04 | -1.1% | $3.69 | $3.84 | $3.665 | 13,058,800 | |
| $3.74 | -0.15 | -3.9% | $3.89 | $3.90 | $3.70 | 10,481,300 | |
| $3.89 | +0.19 | +5.1% | $3.65 | $3.90 | $3.61 | 19,338,300 | |
| $3.70 | -0.35 | -8.6% | $4.03 | $4.09 | $3.66 | 23,670,600 | |
| $4.05 | +0.08 | +2.0% | $4.00 | $4.16 | $3.90 | 40,460,400 | |
| $3.97 | +0.14 | +3.7% | $3.92 | $4.015 | $3.83 | 37,728,700 | |
| $3.83 | +0.29 | +8.2% | $3.54 | $3.83 | $3.50 | 44,325,600 | |
| $3.54 | +0.35 | +11.0% | $3.28 | $3.59 | $3.26 | 28,251,200 | |
| $3.19 | -0.05 | -1.5% | $3.26 | $3.31 | $3.16 | 14,813,900 | |
| $3.24 | -0.17 | -5.0% | $3.37 | $3.37 | $3.22 | 11,881,300 | |
| $3.41 | +0.21 | +6.6% | $3.19 | $3.455 | $3.18 | 17,102,500 | |
| $3.20 | +0.04 | +1.3% | $3.21 | $3.25 | $3.15 | 8,034,100 | |
| $3.16 | -0.055 | -1.7% | $3.14 | $3.25 | $3.10 | 10,617,000 | |
| $3.215 | -0.225 | -6.5% | $3.42 | $3.45 | $3.21 | 14,198,900 | |
| $3.44 | -0.19 | -5.2% | $3.58 | $3.59 | $3.43 | 14,990,200 | |
| $3.63 | +0.19 | +5.5% | $3.415 | $3.70 | $3.41 | 29,039,100 | |
| $3.44 | +0.06 | +1.8% | $3.435 | $3.45 | $3.29 | 13,746,100 | |
| $3.38 | +0.05 | +1.5% | $3.34 | $3.489 | $3.285 | 14,052,700 | |
| $3.33 | -0.07 | -2.1% | $3.34 | $3.38 | $3.28 | 9,991,900 | |
| $3.40 | +0.06 | +1.8% | $3.305 | $3.41 | $3.25 | 13,903,400 | |
| $3.34 | -0.10 | -2.9% | $3.40 | $3.45 | $3.31 | 10,560,600 | |
| $3.44 | -0.05 | -1.4% | $3.515 | $3.55 | $3.42 | 10,986,800 | |
| $3.49 | -0.07 | -2.0% | $3.51 | $3.55 | $3.43 | 12,978,400 | |
| $3.56 | +0.31 | +9.5% | $3.27 | $3.59 | $3.26 | 22,516,700 | |
| $3.25 | -0.25 | -7.1% | $3.42 | $3.44 | $3.215 | 15,155,100 | |
| $3.50 | +0.16 | +4.8% | $3.39 | $3.63 | $3.37 | 22,898,500 | |
| $3.34 | -0.16 | -4.6% | $3.40 | $3.46 | $3.27 | 21,453,700 |
- Ticker
- BX Swiss:RXRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BX Swiss
- Currency
- CHF
What changed lately
Latest news release · Nov 18, 2026
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Latest earnings call · Nov 3, 2026
Recursion Pharmaceuticals (NASDAQ:RXRX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 3, 2026
Q3 2026 Earnings Presentation
Earnings · 52 slides
Latest news
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Nov 18, 2026
Closed $2.83 (+3.9%) on Nov 18, 2026
Recursion to Participate in Upcoming Investor Conferences
Nov 11, 2026
Closed $3.59 (+1.1%) on Nov 11, 2026
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
Nov 2, 2026
Closed $3.68 (-3.9%) on Nov 3, 2026
Recursion Appoints Fred Hassan as Chair of the Board
Nov 2, 2026
Closed $3.68 (-3.9%) on Nov 3, 2026
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Oct 26, 2026
Closed $4.05 (+6.6%) on Oct 27, 2026
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Oct 15, 2026
Closed $4.16 (+11.2%) on Oct 15, 2026
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Oct 15, 2026
Closed $4.16 (+11.2%) on Oct 15, 2026
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Oct 15, 2026
Closed $4.16 (+11.2%) on Oct 15, 2026
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Aug 5, 2026
Closed $3.17 (-4.2%) on Aug 5, 2026
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Jul 29, 2026
Closed $2.97 (-2.6%) on Jul 29, 2026
Recursion Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 122 in all · newest Nov 18, 2026 · oldest 2021
- Calls
- 10 calls with a replay · 10 with a transcript · latest Nov 3, 2026
- Decks
- 48 decks · latest Nov 3, 2026
Where Recursion Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RXRX · Home listing | NASDAQ | United States | USD |
| BMV:RXRX | BMV | Mexico | MXN |
| BOATS:RXRX | BOATS | United States | USD |
| gettex:A3CM1C | gettex | Germany | EUR |
| BIVA:RXRX | BIVA | Mexico | MXN |
| BX Swiss:RXRX · This page | BX Swiss | Switzerland | CHF |
| Stuttgart:8RL | Stuttgart | Germany | EUR |
Valuation
EV/sales 14.5× against a median of 52.7×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $987.7M USD
- P/E
- Loss
- EV/sales
- 14.5×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.7×
- Gross margin
- 29.2%
- Operating margin
- −725.4%
- Net margin
- −697.1%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.83
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. · NASDAQ:RXRX | US$1.53B | US$987.7M | n/a | 14.5× | n/a | 1.7× | −697.1% | 0.0× | 2.83 |
| Zenas BioPharma, Inc. · NASDAQ:ZBIO | US$1.62B | US$1.26B | n/a | 114× | n/a | 7.6× | n/a | 1.1× | 1.05 |
| Hitgen Inc. Class A · SSE:688222 | US$1.56B | US$1.44B | 66.5× | 13.6× | n/a | 6.5× | 22.1% | 0.2× | n/a |
| Alvotech · NASDAQ:ALVO | US$1.47B | US$2.78B | n/a | 5.7× | 31.4× | n/a | −36.5% | n/a | 0.90 |
| ABL Bio, Inc. · KRX:298380 | US$1.47B | US$1.34B | n/a | 52.7× | n/a | 11.5× | −229.4% | 0.0× | n/a |
| PELL Bio-Med Technology Co Ltd · TWSE:6949 | US$1.46B | US$1.40B | n/a | 1,591× | n/a | 18.7× | n/a | 0.1× | n/a |
| Mesoblast Limited · ASX:MSB | US$1.46B | US$1.42B | n/a | 82.4× | n/a | 2.4× | −593.9% | 0.2× | n/a |
| Damora Therapeutics, Inc. · NASDAQ:DMRA | US$1.44B | US$910.0M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 0.88 |
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.39B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| Median of the others | US$1.46B | US$1.37B | 66.5× | 52.7× | 31.4× | 6.5× | −61.0% | 0.1× | 1.05 |
Forecasts
1 strong buy · 2 buy · 4 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.32 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.88 · 8 analysts
- Revenue, year to Dec 2026
- 40.32M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Najat Khan | CEO and President |
| Ben Taylor | Chief Financial Officer & President Recursion UK |
| Nathan Hatfield | Chief Legal Officer & Corporate Secretary |
| Sid Jain | SVP of Clinical Development & Data Science |
| Ben Mabey | Chief Technology Officer |
| David Hallett | Chief Scientific Officer |
| Erica Fox | Chief People and Impact Officer |
| Matt Kinn | Chief Business Officer |
| Ryan Kelly | Chief Communications Officer |
| Vicki Goodman | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Fred Hassan | Chair of the Board |
| Blake Borgeson | Board Member |
| Dean Li | Board Member |
| Elaine Sun | Board Member |
| Franziska Michor | Board Member |
| Namandjé Bumpus | Board Member |
| Robert Hershberg | Board Member |
| Zachary Bogue | Board Member |
| Zavain Dar | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q3 2026 Earnings Call | Tue, Nov 03, 2026 · 8:00 AM ET | Replay |
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 8:00 AM ET | Replay |
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q1 2026 Earnings Call | Wed, May 06, 2026 · 8:00 AM ET | Replay |
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q4 2025 Earnings Call | Wed, Feb 25, 2026 · 8:00 AM ET | Replay |
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 8:00 AM ET | Replay |
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 8:00 AM ET | Replay |
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q1 2025 Earnings Call | Mon, May 05, 2025 · 8:00 AM ET | Replay |
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q4 2024 Earnings Call | Fri, Feb 28, 2025 · 8:30 AM ET | Replay |
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 5:00 PM ET | Replay |
| Recursion Pharmaceuticals (NASDAQ:RXRX) Q1 2024 Earnings Call | Thu, May 09, 2024 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 2, 2026 · After close | −3.9% |
| Q2 2026 | Aug 5, 2026 · Before open | −4.2% |
| Q1 2026 | May 6, 2026 · Before open | +1.8% |
| Q4 2025 | Feb 25, 2026 | +6.8% |
| Q3 2025 | Nov 5, 2025 · Before open | −0.8% |
| Q2 2025 | Aug 5, 2025 · Before open | −4.7% |
| Q1 2025 | May 5, 2025 · Before open | −16.6% |
| Q4 2024 | Feb 25, 2025 · Before open | −9.6% |
| Q3 2024 | Nov 6, 2024 · After close | −0.6% |
| Q2 2024 | Aug 8, 2024 · Before open | +4.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −0.5% |
| Q4 2023 | Feb 27, 2024 · After close | −16.6% |
| Q3 2023 | Nov 9, 2023 · Before open | −7.1% |
| Q2 2023 | Aug 8, 2023 · Before open | +4.7% |
| Q1 2023 | May 8, 2023 · Before open | +8.5% |
| Q4 2022 | Feb 27, 2023 · After close | +5.6% |
| Q3 2022 | Nov 8, 2022 · After close | +6.7% |
| Q2 2022 | Aug 9, 2022 · After close | +12.0% |
| Q1 2022 | May 10, 2022 · After close | −11.4% |
| Q4 2021 | Mar 23, 2022 · Before open | −1.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 52 slides | Nov 3, 2026 |
| Investor Presentation (October 2026) | Investor deck | 44 slides | Oct 15, 2026 |
| Corporate Update (August 2026) | Corporate update | 66 slides | Aug 5, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 38 slides | Aug 5, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 34 slides | May 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 70 slides | May 6, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 44 slides | Feb 25, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 34 slides | Jan 12, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 32 slides | January 2026 |
| Technical Presentation (December 2025) | Technical | 42 slides | Dec 8, 2025 |
All 48 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2025) | Investor deck | 49 slides | Nov 5, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 30 slides | Nov 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 32 slides | Aug 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 32 slides | Aug 5, 2025 |
| Investor Presentation (June 2025) | Investor deck | 29 slides | Jun 10, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 54 slides | May 5, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 51 slides | May 5, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 85 slides | Feb 28, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 70 slides | Jan 13, 2025 |
| Investor Presentation (November 2024) | Investor deck | 70 slides | Nov 20, 2024 |
| Q3 2024 Earnings Presentation | Earnings | 90 slides | Nov 6, 2024 |
| Merger or Acquisition (October 2024) | Merger or acquisition | 92 slides | Oct 2, 2024 |
| Merger or Acquisition (September 2024) | Merger or acquisition | 92 slides | Sep 3, 2024 |
| Merger or Acquisition (August 2024) | Merger or acquisition | 115 slides | Aug 8, 2024 |
| Merger or Acquisition (August 2024) | Merger or acquisition | 93 slides | Aug 8, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 20 slides | Aug 8, 2024 |
| Investor Day (June 2024) | Investor day | 179 slides | Jun 24, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 101 slides | May 9, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 15 slides | May 9, 2024 |
| Q4 2023 Earnings Presentation | Earnings | 102 slides | Feb 27, 2024 |
| FY2023 Earnings Presentation | Earnings | 37 slides | Feb 27, 2024 |
| Conference Presentation (January 2024) | Conference | 104 slides | Jan 8, 2024 |
| Investor Presentation (December 2023) | Investor deck | 97 slides | Dec 20, 2023 |
| Investor Presentation (October 2023) | Investor deck | 94 slides | Oct 2, 2023 |
| Investor Presentation (September 2023) | Investor deck | 94 slides | Sep 5, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 92 slides | Aug 8, 2023 |
| Investor Presentation (June 2023) | Investor deck | 87 slides | Jun 13, 2023 |
| Q4 2022 Earnings Presentation | Earnings | 85 slides | Feb 27, 2023 |
| Investor Day (January 2023) | Investor day | 143 slides | Jan 25, 2023 |
| JP Morgan Healthcare Conference 2023 | Conference | 37 slides | Jan 10, 2023 |
| Q3 2022 Earnings Presentation | Earnings | 40 slides | Nov 8, 2022 |
| Investor Presentation (October 2022) | Investor deck | 40 slides | Oct 25, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 34 slides | Aug 9, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 36 slides | May 10, 2022 |
| Q4 2021 Earnings Presentation | Earnings | 34 slides | Mar 23, 2022 |
| Investor Presentation (January 2022) | Investor deck | 34 slides | Jan 10, 2022 |
| Investor Presentation (November 2021) | Investor deck | 45 slides | Nov 10, 2021 |
| Q2 2021 Earnings Presentation | Earnings | 45 slides | Sep 9, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of class A common stock Announced: about US$200M · US$3.25 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), Goldman Sachs & Co. LLC (co-lead), Morgan Stanley & Co. LLC (co-lead), Evercore Group L.L.C. (co-lead), Needham & Company, LLC Buyers: Janus Henderson Investors; Invus; Longaeva Partners; ARK Invest; Driehaus Capital Management Use of proceeds: Advance highest-conviction programs and deliver on upcoming clinical milestones | Oct 15, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Apr 15, 2021.
- Price
- US$18.00 a share
- Shares offered
- 24,242,424 shares of Class A common stock
- Offering size
- US$436.4 million
- Underwriters' option
- Up to 3,636,363 more shares
- Underwriters
- Goldman Sachs & Co. LLC, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Company LLC, KeyBanc Capital Markets · In the order on the cover
- Shares delivered
- On or about Apr 20, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 26, 2021 |
| Filed publicly | Mar 22, 2021 |
| Amended twice | Newest Apr 15, 2021 |
| Shares registered with an exchange | Apr 12, 2021 |
| Declared effective by the SEC | Apr 15, 2021 |
| Final prospectus, with the price | Apr 16, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 16, 2021 |
| EFFECT · Notice that a registration is effective | Apr 15, 2021 |
| S-1MEF · Registration of more shares for the same offering | Apr 15, 2021 |
| CERT · Exchange's certificate of listing | Apr 15, 2021 |
| S-1/A · Registration statement, amended | Apr 15, 2021 |
| CORRESP · Letter to the SEC | Apr 13, 2021 |
| CORRESP · Letter to the SEC | Apr 13, 2021 |
| S-1/A · Registration statement, amended | Apr 12, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 12, 2021 |
| CORRESP · Letter to the SEC | Mar 22, 2021 |
All 16 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Mar 22, 2021 |
| UPLOAD · Letter from the SEC | Mar 19, 2021 |
| DRSLTR · Letter to the SEC with a draft | Mar 3, 2021 |
| DRS/A · Draft registration statement, amended | Mar 3, 2021 |
| UPLOAD · Letter from the SEC | Feb 22, 2021 |
| DRS · Draft registration statement | Jan 26, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 16, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 74.7M | 58.8M | 44.6M | 39.8M | 10.2M | 3.96M | 2.32M |
| Cost of revenue | 71.0M | 45.2M | 42.6M | 48.3M | 0 | 0 | |
| Gross profit | 3.73M | 13.6M | 1.99M | -8.43M | 10.2M | 3.96M | |
| Research and development | 475.3M | 314.4M | 241.2M | 155.7M | 135.3M | 63.3M | 45.8M |
| Operating income | -648.1M | -479.0M | -350.1M | -245.7M | -182.8M | -84.6M | -62.4M |
| Depreciation and amortization | 83.7M | 36.5M | 24.4M | 11.8M | 8.40M | 3.94M | 2.49M |
| EBITDA | -564.4M | -442.5M | -325.7M | -234.0M | -174.4M | -80.7M | -60.0M |
| Interest expense | 1.81M | 1.57M | 97.0K | 55.0K | 2.95M | 1.36M | 635.0K |
| Income before tax | -644.9M | -464.8M | -332.1M | -239.5M | -186.5M | ||
| Income tax | -136.0K | -1.13M | -4.06M | 0 | 0 | 0 | 0 |
| Net income | -644.8M | -463.7M | -328.1M | -239.5M | -186.5M | -87.0M | -61.9M |
| Earnings per share, basic | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 | -3.99 | -2.87 |
| Earnings per share, diluted | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 | -3.99 | -2.87 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 743.3M | 594.4M | 391.6M | 549.9M | 285.1M | 262.1M | 75.2M |
| Short-term investments | 0 | 231.4M | 0 | ||||
| Receivables | 0 | 34.0K | 156.0K | ||||
| Current assets | 812.8M | 714.3M | 438.1M | 569.8M | 534.7M | 266.4M | |
| Property, plant and equipment | 103.9M | 141.1M | 86.5M | 88.2M | 64.7M | 26.0M | |
| Goodwill | 162.2M | 148.9M | 52.1M | 801.0K | 801.0K | 801.0K | |
| Total assets | 1.47B | 1.45B | 653.7M | 701.3M | 610.3M | 298.6M | |
| Accounts payable | 18.1M | 21.6M | 3.95M | 4.59M | 2.82M | 1.07M | |
| Current liabilities | 147.7M | 187.5M | 93.2M | 100.3M | 46.7M | 23.1M | |
| Long-term debt | 9.56M | 19.0M | 1.10M | ||||
| Total debt | 9.09M | 8.43M | 41.0K | 723.0K | |||
| Total liabilities | 343.3M | 413.8M | 190.3M | 215.5M | 67.4M | 56.6M | |
| Shareholders' equity | 1.13B | 1.03B | 463.4M | 485.8M | 542.9M | -206.3M | -124.3M |
| Shares outstanding | 528.2M | 396.8M | 234.3M | 191.0M | 170.3M | 22.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -371.8M | -359.2M | -287.8M | -83.5M | -158.6M | -45.4M | -57.0M |
| Capital spending | -6.47M | -13.7M | -12.0M | -37.1M | -39.8M | -5.83M | -3.91M |
| Free cash flow | -378.3M | -372.9M | -299.7M | -120.6M | -198.4M | -51.2M | -61.0M |
| Cash from investing | -16.9M | 260.1M | -10.2M | 193.2M | -271.7M | -8.74M | -3.91M |
| Cash from financing | 521.5M | 304.1M | 140.1M | 154.3M | 458.5M | 246.1M | 120.4M |
| Change in cash | 150.9M | 201.6M | -157.7M | 263.8M | 28.2M | 192.0M | 59.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 2, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 2, 2026 | Results | SEC |
| 424B5 · Prospectus | Oct 15, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 15, 2026 | Results | SEC |
| 424B5 · Prospectus | Oct 15, 2026 | Offer document | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 21, 2026 | Material contract | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 29, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Apr 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 25, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 25, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Feb 25, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 25, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 4, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 3, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 23, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| 424B7 · Prospectus | Nov 26, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 29, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2025 | Other filings | SEC |
| 8-K/A · Current report, amended | Aug 29, 2025 | Financing | SEC |
| 424B7 · Prospectus | Aug 29, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
This page holds 200 of 996 filings. Open Filings
Cap table
Built by 6ix from Recursion Pharmaceuticals, Inc.’s releases · as of Oct 26, 2026
- Common shares
- 622,759,259
- Fully diluted
- 622,759,259
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 622,759,259 | Oct 26, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 26, 2026 | 622,759,259 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Hershberg Other companies: Danaher Corporation (Director · Since at least Nov 15, 2026); AtaiBeckley Inc. (Director · Since at least Jun 4, 2026); Hillevax Inc (President and CEO, Director · Since at least Apr 28, 2022); Adaptive Biotechnologies Corporation (Board Member · Since at least Jun 26, 2019); ARS Pharmaceuticals, Inc. (Director · Dec 3, 2020 – Jun 10, 2022 · Past); Fate Therapeutics, Inc. (Director · May 1, 2020 – Jun 6, 2023 · Past); NanoString Technologies Inc (Director · Mar 2, 2015 – Apr 18, 2022 · Past); Dendreon Corp (Sr. VP & Chief Medical Officer · Dec 31, 2005 – Jan 19, 2006 · Past) | Board Member · Since at least Apr 15, 2021 |
| Fred Hassan Other companies: EyePoint, Inc. (Director · Since at least Sep 3, 2024); Cocrystal Pharma, Inc. (Director · Since at least Apr 20, 2023); BridgeBio Pharma, Inc. (Director · Since at least Aug 17, 2021); Precigen, Inc. (Director · Since at least Jun 30, 2016); Prometheus Biosciences Inc (Director · May 14, 2021 – Jun 16, 2023 · Past); Time Warner Inc (Director · Jun 1, 2016 – Jun 14, 2018 · Past); Amgen Inc. (Director · Jul 28, 2015 – May 5, 2020 · Past) | Director · Since Oct 31, 2026 |
| David J Mauro Other companies: Codiak BioSciences Inc (Chief Medical Officer · May 2, 2022 – Jan 24, 2023 · Past); Prelude Therapeutics Incorporated (Chief Medical Officer · Sep 24, 2020 – Oct 5, 2021 · Past); Advaxis Inc (Chief Medical Officer · Oct 20, 2014 – Dec 31, 2015 · Past) | Chief Medical Officer · Jun 1, 2023 – Nov 15, 2024 · Past |
| Elaine Sun Other companies: Dynavax Technologies Corporation (Director · Since at least Dec 10, 2021); Halozyme Therapeutics, Inc. (SVP, Chief Financial Officer · Mar 2, 2020 – Apr 1, 2021 · Past) | Board Member · Since at least Mar 15, 2025 |
| Fred Hassan Other companies: Cocrystal Pharma, Inc. (Director · Since at least Oct 30, 2025); EyePoint, Inc. (Board Member · Since at least Nov 7, 2024) | Chair of the Board · Since at least Nov 2, 2026 |
| R. Martin Marty Chávez Other companies: Alphabet Inc (Google) Class C (Board Member · Since at least Jul 11, 2022); Goldman Sachs Group, Inc. (the) (Executive Vice President - CFO · May 1, 2017 – Feb 7, 2018 · Past) | Director · Apr 15, 2021 – Apr 1, 2024 · Past |
| Terry-Ann Burrell Other companies: Rapport Therapeutics, Inc. (Director · Jun 6, 2024 – Jun 6, 2024 · Past); Beam Therapeutics Inc. (Chief Financial Officer · Feb 5, 2020 – Apr 26, 2024 · Past) | Director · Apr 15, 2021 – Jul 1, 2024 · Past |
| Ben R Taylor Other companies: Tyme Technologies Inc (President, CFO · Jul 27, 2017 – May 7, 2020 · Past) | Chief Financial Officer · Since at least Nov 20, 2024 |
| Chris Gibson Other companies: Pacific Biosciences of California, Inc. (Director · Mar 5, 2026 – Nov 5, 2026 · Past) | Director · Mar 5, 2026 – Nov 5, 2026 · Past |
| Christopher Gibson Other companies: Pacific Biosciences of California, Inc. (Director · Since at least Mar 3, 2026) | Director · Since at least Apr 15, 2021 |
All 30 people
| Person | Seat |
|---|---|
| Dean Li Other companies: Merck & Company, Inc. (Executive VP & President, MRL · Since at least Jan 1, 2021) | Board Member · Since at least Apr 15, 2021 |
| Michael Secora Other companies: Iambic Therapeutics, Inc. (Chief Financial Officer and Chief Corporate Development Officer · Since at least Oct 16, 2026) | Chief Financial Officer · Apr 15, 2021 – Nov 15, 2024 · Past |
| Ben Mabey | Chief Technology Officer · Since at least Nov 12, 2024 |
| Ben Taylor | Chief Financial Officer & President Recursion UK · Since at least May 5, 2025 |
| Blake Borgeson | Board Member · Since at least Apr 15, 2021 |
| David Hallett | Chief Scientific Officer · Since at least Jul 8, 2025 |
| Erica Fox | Chief People and Impact Officer · Since at least Nov 6, 2024 |
| Franziska Michor | Board Member · Since at least Nov 20, 2024 |
| Matt Kinn | Chief Business Officer · Since at least Nov 4, 2026 |
| Najat Khan | CEO and President · Since at least Apr 16, 2024 |
| Namandjé Bumpus | Board Member · Since at least May 5, 2025 |
| Nathan Hatfield | Chief Legal Officer & Corporate Secretary · Since at least Nov 4, 2026 |
| Ramona Doyle | Chief Medical Officer · Apr 15, 2021 – May 16, 2022 · Past |
| Ryan Kelly | Chief Communications Officer · Since at least Jul 29, 2026 |
| Shafique Virani | Chief Business Officer · Apr 15, 2021 – Jan 16, 2024 · Past |
| Sid Jain | SVP of Clinical Development & Data Science · Since at least Nov 4, 2026 |
| Tina Marriott | President and COO · Apr 15, 2021 – Nov 15, 2024 · Past |
| Vicki Goodman | Chief Medical Officer · Since at least Oct 26, 2026 |
| Zachary Bogue | Board Member · Since at least Apr 15, 2021 |
| Zavain Dar | Board Member · Since at least Apr 15, 2021 |
Log in to ask 6ix AI your own questions about Recursion Pharmaceuticals, Inc.